Cohesion Appoints Thomas M. Prescott to Its Board of Directors.

Business Editors & Medical/Science Writers

PALO ALTO, Calif.--(BW HealthWire)--Sept. 7, 2000

Cohesion Technologies, Inc. (NASDAQ NM:CSON) - a leader in the development of proprietary surgical hemostats, sealants, adhesives and adhesion prevention barriers - today announced that Thomas M. Prescott (45) has joined the Company's Board of Directors, increasing the size of the Board to nine members.

Since May 1999, Mr. Prescott has served as President, Chief Executive Officer and a Director of Cardiac Pathways (NASDAQ NM: CPWY), a manufacturer of minimally invasive systems to diagnose and treat abnormally rapid heart rhythms.

Previously, Mr. Prescott was Vice President and General Manager of a $200 million respiratory business unit of Nellcor Puritan Bennett. While running this business, he led a major turnaround by driving substantial growth through new products and consolidating operations to return the business to profitability. Mallinckrodt acquired Nellcor Puritan in September 1997. Mr. Prescott also held various positions of increasing responsibility at GE Medical Systems, and has worked in the medical device and technology space since 1981.

"For nearly 20 years, Tom has demonstrated his talents in high growth and new product general management, sales and marketing assignments at firms ranging from start-ups to world-class global leaders. He is recognized as a successful operations executive, beginning with his General Electric management training early in his career," stated David Foster, chief executive officer of Cohesion Technologies. "His experience in the medical device industry is considerable, and we look forward to the insight he will bring to Cohesion Technologies particularly as we drive for growth through launching new products, expanding marketing and ramping-up manufacturing."

Mr. Prescott holds a BS in Engineering from Arizona State University and an Executive MBA from Northwestern University's Kellogg Graduate School of Management.

Cohesion Technologies discovers, develops and commercializes innovative resorbable biodevices, adhesive technologies and delivery systems in the fields of tissue repair and regeneration. The Company is developing products for the estimated $1.3 billion worldwide surgical hemostasis and sealant markets. For more information on Cohesion Technologies, please visit the Company's Web site at www.cohesiontech.com.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "anticipates," "estimates," "projects," "believes," "intends," "expects" and similar words and phrases. Actual results are subject to risks and uncertainties, including the timing of product introductions, the success of scaling up product production, the timing and terms of sales arrangements with other companies, performance of third-party sales representatives, receipt of regulatory approvals, including approvals from the FDA, clinical efficacy of and market demand for products, results of clinical studies and potential unfavorable publicity regarding Cohesion Technologies or its products, among other matters discussed in this release. Such differences may be based upon factors within the Company's control, such as strategic planning decisions by management and reallocation of internal resources, or on factors outside the Company's control, such as scientific advances by third parties, introduction of competitive products and delays by regulatory authorities, including approvals from the FDA. Please see the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. The Company disclaims any obligation to update any of the forward-looking statements contained herein to reflect future events or developments.